Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
New law shields California college students who seek help after overdosing
BY THE OPTIMIST DAILY'S EDITORIAL TEAM When TJ McGee overdosed in his UC Berkeley dorm room two years ago, his roommates hesitated before calling ...
Read MoreSpeed friending: one cafe’s answer to America’s growing friendshi...
BY THE OPTIMIST DAILY'S EDITORIAL TEAM Something has shifted over the past three decades in how Americans relate to each other. In 1990, about ...
Read MoreDeforestation declines in Brazilian Amazon the first month of Lula’s rule
The rate of deforestation in Brazil's Amazon rainforest decreased in January compared to the same month a year ago, satellite data revealed on Friday, ...
Read MoreFrom guerrilla fighters to beer brewers: former FARC members craft peace in e...
In the center of Bogotá, La Trocha Brewery, an unexpected company started by former Revolutionary Armed Forces of Colombia (FARC) militants, is more than ...
Read More
